PHV thrombosis in pregnancy

Gautam Agarwal, Rajesh Jose, Praveen Varma





Effective anticoagulation is critical in patients with prosthetic heart valve [PHV], but remains challenging in pregnancy because both oral anticoagulation and heparin are associated with important fetal and maternal risks.



Herein we reported a case of 23-year-old pregnant woman presented with PHV thrombosis during late second trimester and complicated by Immune mediated thrombocytopenia.



She underwent Redo MVR [25mm CE Perimount Plus Pericardial Bioprosthetic valve] + LSCS. Peri operatively she was managed with Platelet transfusions/ Immunoglobulins/ Steroid pulse therapy and recovered well.

Full Text:



Schwartzenberg S, Perlman S, Levy R, Elkayam U, Goland S - J. Heart Valve Dis. - July 1, 2013; 22 (4); 603-6

Taner Ulus, Utku Senol, Alparslan Birdane and Yuksel Cavusoglu, PP-171 The Use of Low Molecular Weight Heparin During Pregnancy in Patients with Mechanical Heart Valves Carries Potential Risk for Valve Thrombosis: A Report of Three Cases, American Journal of Cardiology, The, 2015-03-16, Volume 115, Pages S172-S172

Rowan J.A., McCowan L.M., Raudkivi P.J., and North R.A.: Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol 2001; 185: pp. 633-637

Oran B., Lee-Parritz A., and Ansell J.: Low molecular weight heparin for the prophy-laxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 2004; 92: pp. 747-751

Chan W.S., Anand S., and Ginsberg J.S.: Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160: pp. 191-196

Abildgaard U., Sandset P.M., Hammerstrom J., Gjestvang F.T., and Tveit A.: Man-agement of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Thromb Res 2009; 124: pp. 262-267

Bates S.M., Greer I.A., Hirsh J., and Ginsberg J.S.: Use of antithrombotic agents dur-ing pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: pp. 627S-644S

Barbour L.A., Oja J.L., and Schultz L.K.: A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of antico-agulation. Am J Obstet Gynecol 2004; 191: pp. 1024-1029


  • There are currently no refbacks.